Sinovac names Nan Wang to position of CFO

Sinovac Biotech, Ltd., a China-based biopharmaceutical company, announced last week that Nan Wang, the company's vice president, has been appointed to the position of chief financial officer.

The change was made effective on Saturday after Danny Chung, the company's former CFO, resigned from the position for family reasons. Weidong Yin, the chairman, president and CEO of Sinovac, praised Wang for her work in the company's vaccine sector.

"For more than twelve years, Nan has served as a valuable member of Sinovac's senior management team and developed a wealth of experience in the vaccine sector, communications with investors, fundraising, and financial management," Yin said. "We believe her business experience will bring additional value to the finance team as the company prepares to grow with the introduction of new products. On behalf of the board, we appreciate Danny's contributions to the company and wish Danny all the best in his future endeavors."

Wang served the Sinovac in multiple senior management roles, including as the vice general manager of operating subsidiary Sinovac Beijing, general manager of Sinovac Dalian and as a member of the board of directors of Sinovac Dalian and Sinovac Beijing. Sinovac said Wang was instrumental in leading the company's successful public offering in early 2010.

Sinovac researches, develops, manufactures and commercializes vaccines against diseases such as mumps, H1N1 influenza, H5N1 pandemic influenza, seasonal influenza, hepatitis A and hepatitis B. Sinovac recently concluded a Phase III clinical trial for an enterovirus 71 vaccine against hand, foot and mouth disease.